Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention

Current Vascular Pharmacology

Volumn 7, Issue 3, 2009, Pages 264-266

  Athyros, Vasilios G ^a   Tziomalos, Konstantinos ^b   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AURORA; Cardiovascular disease risk; End stage renal disease; Hemodialysis; Rosuvastatin; Statins

Indexed keywords

ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; EARLY INTERVENTION; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; RENAL PROTECTION; RISK REDUCTION; SUDDEN DEATH; TREATMENT DURATION; CHRONIC KIDNEY FAILURE; DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; SULFONAMIDES;

EID: 69149107719     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109788340712     Document Type: Editorial

References (31)

1. Centers for Disease Control and Prevention (CDC). Hospitalization discharge diagnoses for kidney disease - United States, 1980-2005. MMWR Morb Mortal Wkly Rep 2008; 57: 309-12.
2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. Am Soc Nephrol 2005; 15: 1307-15.
3. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61: 297-304.
4. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 336: 645-51.
5. Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006; 26: 523-39.
6. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005; 45: 119-26.
7. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
8. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-38.
9. Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008; 6: 93-107.
10. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al.; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-407.
11. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
12. Siew ED, Ikizler TA. Determinants of insulin resistance and its effects on protein metabolism in patients with advanced chronic kidney disease. Contrib Nephrol 2008; 161: 138-44.
13. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. JUPITER: major implications for vascular risk assessment. Curr Med Res Opin 2009; 25: 133-7.
14. Strippoli GFM, Craig JC. Sunset for statins after AURORA? N Engl J Med 2009; 360: 1455-7.
15. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003; 84: S207-S210.
16. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 2008; 51: 2375-84.
17. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol- lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
18. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins vs untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
19. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al.; GREACE Study Collaborative Group. The effect of statins vs untreated dyslipidaemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Am J Kidney Dis 2004; 43: 589-99.
20. Athyros VG, Karagiannis A, Liberopoulos EN, Elisaf M, Mikhailidis DP. Statin treatment may be beneficial to both the kidneys and the heart. Perit Dial Int 2007; 27: 215-6.
21. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51: 1448-54.
22. Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, et al.; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008; 83: 870-9.
23. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
24. Feringa HH, Karagiannis SE, Chonchol M, Vidakovic R, Noordzij PG, Elhendy A, et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 2007; 18: 1872-9.
25. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, et al.; GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004; 18: 781-8.
26. Athyros VG, Karagiannis A, Kakafika A, Elisaf M, Mikhailidis DP. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant 2007; 22: 963-4.
27. Karagiannis A, Mikhailidis DP, Athyros VG, Kakafika AI, Tziomalos K, Liberopoulos EN, et al. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin Ther Targets 2007; 11: 191-205.
28. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al.; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.
29. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-9.
30. Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 2007; 10: 433-42.
31. Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004; 141: 95-101.